▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2482 by analyst upside · 2026-10-16
HRMY
Harmony Biosciences Holdings, Inc.
Healthcare · Market Cap $2B · P/E 12.3x
ANALYST PRICE TARGET
+26.1%
implied upside to consensus target
Current Price $38.27
Consensus Target $48.25
Bull Target $70.0
Bear Target $30.0
Analysts Covering 12
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
6
Hold
3
Sell
1
52-Week Low $25.52
52-Week High $43.49
YTD Return +2.4%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) 12.3x
Forward P/E 5.5x
EPS (TTM) $3.10
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $960M
Profit Margin 18.9%
52-WEEK RANGE
52-Week Low $25.52
52-Week High $43.49
Current Price $38.27
Bear Target $30.0
Bull Target $70.0
● Now $38.27 ● Target $48.25
TRADING DATA
Avg Volume 896K
YTD Return +2.4%
Analyst Count 12
Consensus Buy
Upside to Target +26.1%
Last Updated 2026-10-16

ANALYST SUMMARY

Harmony Biosciences Holdings, Inc. (HRMY) is currently trading at $38.27 with a Wall Street consensus price target of $48.25, implying potential upside of 26.1% over the next 12 months. 12 analysts currently cover HRMY, with a consensus rating of Buy - 67% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $70.0, while the most cautious has a target of $30.0.

HRMY operates in the Healthcare sector with a market capitalisation of $2B. The stock is up 2.4% year-to-date and is currently trading near the upper end of its 52-week range of $25.52 – $43.49.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for HRMY, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Wolfe Research ● Initiated
Outperform 2026-08-26 Building track record
Truist Securities - Reiterated
Hold → Hold 2026-08-05 Building track record
Needham - Reiterated
Buy → Buy 2026-08-04 20% win rate (5 calls)
Mizuho - Reiterated
Outperform → Outperform 2026-07-31 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-07-16 31% win rate (48 calls)
Deutsche Bank - Reiterated
Hold → Hold 2026-06-30 Building track record
Truist Securities - Reiterated
Hold → Hold 2026-05-08 Building track record
UBS - Reiterated
Neutral → Neutral 2026-02-25 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
43
out of 100
Coverage depth
20/30
Consensus clarity
9/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →